Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma

2012 ◽  
Vol 40 (7) ◽  
pp. 521-527 ◽  
Author(s):  
Jean El-Cheikh ◽  
Roberto Crocchiolo ◽  
Sabine Furst ◽  
Patrick Ladaique ◽  
Luca Castagna ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
High Risk ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Allogeneic Stem Cell Transplantation ◽  
Reduced Intensity Conditioning ◽  
Reduced Intensity ◽  
Donor Lymphocytes

Death of frontline allo-SCT in myeloma

Blood ◽  
2012 ◽  
Vol 119 (26) ◽  
pp. 6178-6179 ◽  
Author(s):  
Philippe Moreau
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Allogeneic Stem Cell Transplantation ◽  
Reduced Intensity Conditioning ◽  
No Donor ◽  
Comparison Trial ◽  
Frontline Therapy ◽  
Reduced Intensity

In this issue of Blood, Lokhorst et al report the results of a donor versus no-donor comparison trial, which unambiguously establishes that reduced intensity conditioning allogeneic stem cell transplantation (RIC allo-SCT) should not be offered as part of frontline therapy in multiple myeloma (MM).1

Sign in / Sign up

Export Citation Format

Share Document